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Abstract
Background: Nevirapine and lamivudine given to mothers are transmitted to infants via breastfeeding in quantities
sufficient to have biologic effects on the virus; this may lead to an increased risk of a breastfed infant’s development of
resistance to maternal antiretrovirals. The Kisumu Breastfeeding Study (KiBS), a single-arm open-label prevention of mother-
to-child HIV transmission (PMTCT) trial, assessed the safety and efficacy of zidovudine, lamivudine, and either nevirapine or
nelfinavir given to HIV-infected women from 34 wk gestation through 6 mo of breastfeeding. Here, we present findings
from a KiBS trial secondary analysis that evaluated the emergence of maternal ARV-associated resistance among 32 HIV-
infected breastfed infants.
Methods and Findings: All infants in the cohort were tested for HIV infection using DNA PCR at multiple study visits during
the 24 mo of the study, and plasma RNA viral load for all HIV-PCR–positive infants was evaluated retrospectively. Specimens
from mothers and infants with viral load .1,000 copies/ml were tested for HIV drug resistance mutations. Overall, 32 infants
were HIV infected by 24 mo of age, and of this group, 24 (75%) infants were HIV infected by 6 mo of age. Of the 24 infants
infected by 6 mo, nine were born to mothers on a nelfinavir-based regimen, whereas the remaining 15 were born to
mothers on a nevirapine-based regimen. All infants were also given single-dose nevirapine within 48 hours of birth. We
detected genotypic resistance mutations in none of eight infants who were HIV-PCR positive by 2 wk of age (specimens
from six infants were not amplifiable), for 30% (6/20) at 6 wk, 63% (14/22) positive at 14 wk, and 67% (16/24) at 6 mo post
partum. Among the 16 infants with resistance mutations by 6 mo post partum, the common mutations were M184V and
K103N, conferring resistance to lamivudine and nevirapine, respectively. Genotypic resistance was detected among 9/9
(100%) and 7/15 (47%) infected infants whose mothers were on nelfinavir and nevirapine, respectively. No mutations were
detected among the eight infants infected after the breastfeeding period (age 6 mo).
Conclusions: Emergence of HIV drug resistance mutations in HIV-infected infants occurred between 2 wk and 6 mo post
partum, most likely because of exposure to maternal ARV drugs through breast milk. Our findings may impact the choice of
regimen for ARV treatment of HIV-infected breastfeeding mothers and their infected infants.
Trial Registration: ClinicalTrials.gov NCT00146380
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Introduction
Worldwide in 2009, an estimated 370,000 infants acquired HIV
infection primarily because of mother-to-child transmission
(MTCT) in utero, during the peripartum period, or via
breastfeeding [1,2]. MTCT HIV transmission rates range from
25%–40% without antiretroviral medications, 8%–10% when
short-course antiretrovirals are given during the peripartum
period, and less than 5% when triple-combination maternal
antiretroviral therapy is given throughout pregnancy [3]. In sub-
Saharan Africa, progress has been made in the last few years
toward expanding prevention of mother-to-child transmission
(PMTCT) programs with simpler and shorter antiretroviral
prophylactic regimens than those used in industrialized countries
[4,5]. Additionally, many country guidelines include treatment of
eligible HIV-infected pregnant women with triple-combination
antiretroviral therapy to improve the mother’s health and for
PMTCT. More than 95% of HIV-exposed children are born in
resource-limited settings where breastfeeding is the norm [1].
Breastfeeding improves overall infant survival, and safe, feasible,
and sustainable alternatives to breastfeeding are usually unavail-
able. According to WHO, breastfeeding in the first 6 mo of life
provides 4- to 6-fold protection against mortality as opposed to no
breastfeeding [6–8]. Early cessation of breastfeeding in an effort to
limit the exposure to HIV-infected breast milk may be associated
with increased infant morbidity and mortality [9]. The addition of
antiretroviral therapy to HIV-infected mothers through the period
of breastfeeding is one strategy to reduce HIV transmission via
breast milk [10]. The potential mechanisms of protection would
include both reduction in maternal viral load in breast milk as well
as indirect infant prophylaxis by ingestion of antiretrovirals in
breast milk, since several previous studies have shown that
antiretroviral drugs (including zidovudine [ZDV], lamivudine
[3TC], nevirapine [NVP], and efavirenz) administered to nursing
women are present in their breast milk [11–13].
However, the presence of antiretroviral drugs in breast milk may
have negative implications for infants who become infected before
or during breastfeeding, because of the risk of acquisition of drug
resistance caused by viral replication in the presence of low drug
concentrations in the infant. To investigate this risk, we evaluated,
in a secondary analysis, the emergence of drug resistance among
infants born to HIV-infected mothers participating in the Kisumu
Breastfeeding Study (KiBS)—a phase IIb PMTCT single-arm non-
randomized trial that aimed to assess the safety and transmission
rates of a triple-antiretroviral regimen consisting of ZDV, 3TC, and
either NVP or nelfinavir (NFV) from 34 wk gestation through 6 mo
post partum for PMTCT among HIV-infected breastfeeding
mothers [14]. Evaluation of drug levels in the breast milk of a
subset of mothers participating in the trial revealed the presence of
3TC and NVP in quantities sufficient to have therapeutic effect on
HIV (such as prevention of HIV infection or partial suppression of
HIV replication in infected infants and thus potential emergence of
HIV drug resistance) [13]. In this secondary analysis, we evaluated
the emergence of antiretroviral drug resistance mutations among
HIV-infected infants, and ascertained whether resistance mutations
developed as a result of exposure to low doses of maternal
antiretroviral drugs via breastfeeding or whether they were acquired
directly from the mother.
Methods
Detailed description of the study design and methods is
published [14]. In brief, enrollment was conducted between July
2003 and November 2006; follow-up was completed in February
2009. Women were recruited through the PMTCT programs in
the antenatal clinics of the New Nyanza Provincial General
Hospital and the Kisumu District Hospital. Pregnant women were
invited to enroll if they were HIV positive and if, after receiving
risk-benefit counseling on infant-feeding options, they indicated
intent to breastfeed (Text S1).
The study intervention consisted of triple-combination maternal
antiretroviral therapy (ZDV/3TC and either NVP or NFV) given
from 34 wk gestation to 6 mo post partum. Women were
instructed to exclusively breastfeed the infants for 5.5 mo and
then wean over a 2-wk period with complete cessation of
breastfeeding by 6 mo. Women who met World Health
Organization (WHO) criteria for combination antiretroviral
treatment (either with CD4 count ,200/mm3, or WHO stage 3
or 4 HIV disease) [15] at initiation or subsequently through the
study period were continued or reinitiated on antiretroviral
therapy during the 24 mo of follow-up. Participants who did not
meet treatment criteria had antiretroviral therapy discontinued at
6 mo post partum. Infants were initiated on antiretroviral
treatment when they met WHO treatment criteria [15].
Between July 2003 and January 2005 participants received ZDV
300 mg and 3TC 150 mg in a fixed-dose combination tablet
(Combivir, GlaxoSmithKline) taken twice a day and a NVP 200-mg
tablet (Viramune, Boehringer Ingelheim) given in an incremental
dose from one tablet daily for 2 wk and then one tablet twice a day
for the duration of the study [16,17]. Infants received a single 2-mg/
kg dose of NVP liquid (Viramune, Boehringer Ingelheim) within
72 h of birth. In January 2005, the protocol was revised because of
concerns of an increased risk of symptomatic liver toxicity for women
on NVP with CD4.250 cells/ml [18]. Subsequently, participants
with CD4#250 cells/ml received ZDV, 3TC, and NVP as per the
previous regimen, and participants with CD4.250 cells/ml received
ZDV, 3TC as per the previous regimen and the protease inhibitor
(PI), nelfinavir mesylate (NFV) 1,250 mg (as 56250-mg tablets,
Viracept, Hoffman La-Roche Ltd) twice daily.
Ethics Statement
This study was approved by the Ethical Review Committee of
the Kenyan Medical Research Institute as well as the Institutional
Review Board of the US Centers for Disease Control and
Prevention. Written informed consent was obtained from each
participant prior to the study initiation.
Specimen Collection and Laboratory Testing
Maternal and infant whole blood samples were collected in
EDTA-treated anticoagulant vacutainer tubes (Becton Dickinson).
Laboratory visits for blood collections were at delivery (between 0
and 7 d of birth), 2, 6, 14 wk, and 6, 9, 12, 18, and 24 mo. Infant
HIV-PCR testing was done on dried blood spots using Roche DNA
PCR version 1.5 (Roche Diagnostic System). Real-time HIV-PCR
evaluation was done at 14 wk, and 6 and 9 mo. For those infants
who were HIV-PCR positive, we retrospectively tested the earlier
samples to determine the time of first positive HIV-PCR. HIV-1
plasma RNA viral load was quantified from all HIV-infected infant
and mothers’ specimens at multiple study visits, using the Roche
Amplicor HIV-1 monitor version 1.5 (Roche Diagnostic System).
Testing for HIV Drug Resistance and Viral Subtyping
HIV drug resistance mutation analyses of maternal and infant
samples were performed using the FDA licensed ViroSeq HIV-1
genotyping system (Applied Biosystems) retrospectively, starting
with the week 14 specimens from infants with viral load
$1,000 copies/ml. For infants with detectable HIV drug
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resistance mutations at 14 wk, we sequenced the earlier samples
(6, 2, and 0 wk) to determine time of first HIV drug resistance
mutation. For infants with no HIV drug resistance mutations at
14 wk, we tested specimens at 6 mo. For infants who were first
HIV-PCR positive after 14 wk, drug resistance mutation analysis
was done on the first HIV-PCR–positive sample.
After genotyping on the ABI 3100 genetic analyzer, sample file
analysis was performed by the Sequence analysis software version
3.7 (Applied Biosystems). The 1.5-kb pol region sequences were
analyzed with ViroSeq HIV-1 genotyping analysis software
version 2.6 to determine HIV drug resistance mutations, as per
manufacturer’s recommendations. HIV drug resistance mutations
were confirmed to be consistent with the Stanford University HIV
Drug Resistance Database and categorized according to the
International AIDS Society-USA Drug Resistance Mutations
Group December 2008 update [19]. To determine the extent of
genetic diversity and the influence of specific viral subtype on
resistance, the sequences were aligned using the Se-Al multiple
sequence alignment program, Phylogenetic Analysis Using
Parsimony (PAUP)* 4.0b using HIV reference sequences from
GeneBank. HIV-1 inter-subtype recombination was analyzed
using SimPlot software 2.0 and further analyzed by constructing a
neighbor joining, bootstrapped phylogenetic tree, as implemented
in PAUP [20].
Results
Study Population and HIV-PCR Results
Between July 2003 and November 2006, we enrolled 522
pregnant women who met the eligibility criteria, of whom 21
withdrew and one woman died before delivery. The 500 women
delivered 502 live born infants, including nine twin births, one
triplet birth, and nine still births. By 24 mo, 32 infants (all singleton
births) were HIV positive by PCR test with 24 of the infections
having occurred within the first 6 mo of age. Of these 24 infants,
15 were exposed to a maternal NVP-based regimen, whereas nine
were exposed to a maternal NFV-based regimen throughout the
breastfeeding period (Figure 1). One mother changed regimen at
week 14 post delivery from NVP to NFV because of liver toxicity.
The rate and risk factors for HIV-MTCT transmissions in the
KiBS trial are reported separately [14].
Viral Load of the 12 Infants Who Were HIV-PCR Positive at
Birth
Among the 12 infants who were first HIV-PCR positive at
delivery, we analyzed plasma viral load over the 6-mo breastfeed-
ing period. Median viral load at delivery was 2.8 log copies per ml,
decreased ,3-fold at 2 wk, increased ,80-fold from 2 wk to 6 wk,
and remained between 5 and 6 log copies per ml through 6 mo
(Figure 2).
Development of HIV Drug Resistance
Among the 24 infants who were first HIV-PCR positive by 6 mo
(the breastfeeding period), resistance mutations were detected in
none of the eight with detectable viral load at delivery or 2 wk (six
were not amplifiable), in six (30%) of 20 at 6 wk, in 14 (64%) of 22
at 14 wk, and in 16 (67%) of 24 at 6 mo (Table 1). Of the eight
infants who were first HIV-PCR positive after 6 mo (after the
intervention period), none developed drug resistance mutations.
While only acknowledged by two mothers, continued breastfeed-
ing is the most likely cause of infection after 6 mo. However, none
of the eight mothers were taking antiretroviral therapy when the
child was first diagnosed HIV-PCR positive.
HIV Drug Resistance Mutation Patterns by 6 mo
Of the 24 infants with HIV infection diagnosed by 6 mo, seven of
15 (47%) whose mothers were started on NVP and all nine (100%)
of whose mothers were started on NFV, had drug resistance
mutations (p = 0.0095, Fisher exact), but the 95% confidence
interval for the difference was wide (28%–78%). Among the seven
infected infants exposed to maternal NVP who developed resistance
mutations, two (71%) had a mutation conferring resistance to only
the non-nucleoside reverse-transcriptase inhibitors (NNRTI) class of
antiretrovirals, one (14%) had mutations against nucleoside reverse
transcriptase inhibitors (NRTI), while four (57%) had multiclass
drug resistance against both NRTI and NNRTI drugs. Among the
nine HIV-infected infants exposed to maternal NFV, all nine
(100%) had an NRTI mutation, but none had a major PI mutation
or NNRTI mutation (Table 2).
Of the 12 infants who were HIV-PCR positive at delivery, 11
(92%) infants developed HIV drug resistance mutations by 6 mo. Of
the 12 infants who were first HIV-PCR positive from 2 wk to 6 mo of
age, five (42%) infants developed HIV drug resistance mutations by 6
mo, and none of the eight infants first positive from 6 to 24 mo
developed resistance mutations. Of the 16 infants with HIV drug
resistance mutations at 6 mo, 13 (81%) had at least one NRTI
resistance mutation (M184 I/V [n = 12], K65R [n = 2], and D67G
[n = 1]), and six (38%) had NNRTI resistance mutations (K103N
[n = 2], Y181 [n = 2], and G190A [n = 2]) (sequences submitted
to GenBank, http://www.ncbi.nlm.nih.gov/Genbank/index.html,
accession numbers HM164112-HM164123, HM164127-HM164-
128, and HM164130-HM164131) (Table 3). No primary PI
mutations were detected in any infant.
Phylogenetic analysis of the 32 mother–infant pairs demon-
strated subtype distribution as subtype A1 (65.6%), subtype D
(9.4%), subtype C (3.1%), and inter-subtype recombinants
(21.9%). HIV-1 subtypes among the infants with HIV drug
resistance mutations were as follows: 11 (69%) pure subtype A1,
one (6%) subtype D, four inter-subtype recombinants (25%). Of
the four recombinants, three were circulating recombinant forms
(CRFs) A/D and one was CRF D/C. Co-relation between the
mother–infant pair sequences was high with bootstrap values of
.98% and nucleotide similarity of .97%.
Assessment for the Presence of Transmitted HIV Drug
Resistance Mutations
Among the 24 mothers whose infants were first HIV-PCR
positive by 6 mo, ten had undetectable viral load (2.6 log copies/
ml) at 6 mo post partum and 14 had detectable viral load (median,
3.2 log copies/ml; range 1.7–5.9). Among these 14 women, 10
(71%) had no HIV drug resistance mutations and four (29%) had
HIV drug resistance mutations (sequences submitted to GenBank,
http://www.ncbi.nlm.nih.gov/Genbank/index.html, accession
numbers HM164124-HM164126 and HM164129). Two of the
infants born to the four mothers with drug resistance mutations
had infections with wild-type strain at first time of positivity, one
had HIV drug resistance mutations that differed from that of the
mother, and one had overlapping mutation patterns with that of
the mother (6.25%) (Table 4). Of the 24 infants first HIV-PCR
positive by 6 mo, only two were on antiretrovirals for treatment
before 6 mo and both had developed drug resistance mutations
before initiation of antiretroviral therapy.
Discussion
In this study, we investigated the emergence of drug resistance
among HIV-infected breastfeeding infants and found that two-
thirds of infants who became infected before 6 mo developed
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resistance to one or more antiretroviral drugs, most likely because
of exposure to the drugs through the mother’s breast milk.
Previous studies have shown that taking antiretroviral therapy
while breastfeeding significantly reduces the chances that HIV-
infected mothers will transmit the virus to their infants [15,17,21–
26]. However, the infants who get infected (and not put on
antiretroviral therapy soon enough or left untreated) may be at risk
of developing resistance to some of the antiretroviral drugs the
mother is taking. The patterns of HIV viral load in infants and the
timing of detection of HIV drug resistance mutations suggests that
drug-resistant HIV variants were likely not transmitted. As
previously reported by Mirochnick and colleagues [13], 3TC
and NVP given to mothers are transmitted to their infants via
breastfeeding in quantities sufficient to have biologic, but
suboptimal, effect on HIV with potential risk of emergence of
HIV drug resistance [13]. Thus, the HIV drug resistance
mutations reported here likely emerged as a result of exposure
to antiretroviral drugs ingested by the infant either through single-
dose NVP exposure at delivery or indirectly through ingestion of
antiretroviral drugs through breast milk. This possibility has also
been suggested by the findings of the 6-wk extended NVP study
(SWEN) in Uganda, which found the presence of NRTI resistance
in infants provided with NVP prophylaxis while the mothers were
on a triple-antiretroviral regimen [27].
Fourteen infants were first HIV-PCR positive by week 2. Only
eight of the 14, however, had detectable viral load and none of
these had HIV drug resistance mutations detected at the time of
diagnosis of HIV infection. The frequency of HIV drug resistance
mutations increased over time; 30% of HIV-positive infants
developed drug resistance mutations by week 6, 63% by week 14,
and 67% by 6 mo. With only one mother–infant pair having
similar HIV drug resistance patterns and no cases of HIV drug
resistance mutations among the infants first HIV-PCR positive
after the mothers discontinued antiretrovirals, there is little
evidence to suggest that mothers transmitted resistant HIV to
their infants. With single-dose NVP, Eshleman and colleagues [22]
reported a 46% rate of NVP-resistant mutations at 6 wk, and 55%
by 12–14 wk, with subsequent waning by 12 mo using standard
ViroSeq genotyping techniques. In the present study, where
mothers received triple-antiretroviral regimen through 6 mo of
breastfeeding and infants chronically ingested suboptimal quanti-
ties of antiretroviral drugs via breast milk, there were increased
rates of HIV drug resistance mutations in infants at 14 and 24 wk
compared to 6 wk, with no evidence of fading of HIV drug
resistant mutations. It is most likely that the resistance was
maintained over time in the HIV-infected infants because of
ongoing exposure to low quantities of antiretroviral drugs in the
mother’s breast milk.
Our data illustrate a possible relationship between higher viral
load in the HIV-infected infants and emergence of drug resistance
mutations. The viral load at birth was likely partially suppressed
owing to the maternal antiretroviral therapy transferred through
the placenta [13]. The decrease in viral load from delivery to 2 wk
is presumably due to the single-dose NVP given to all infants at
birth and the sharp increase in viral load from 2 wk to 6 wk
coincides with the emergence of HIV drug resistance mutations
from 6 wk to 6 mo (Figure 2).
Kenyan National guidelines and WHO guidelines for early
infant diagnosis recommend testing for HIV at 6 wk [23]. With
wide-scale implementation of early infant HIV diagnosis, breast-
feeding HIV-infected infants could be started on antiretrovirals
different from the maternal antiretrovirals to reduce risk of
development of HIV drug resistance and, therefore, lower
morbidity and mortality among the HIV-infected infants [24]. It
is possible that infection in the first few weeks (not detected by
DNA PCR) could still be affected by drug pressure from the infant
NVP dose, which could contribute to the observed NVP resistance
at 6 wk.
Figure 1. Cohort profile showing mothers enrollment, HIV transmission, and subsequent emergence of drug resistance in infants
born to mothers in the NFV- and NVP-based regimens.
doi:10.1371/journal.pmed.1000430.g001
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One major limitation in this study was that HIV drug resistance
genotyping was performed on maternal plasma samples and not
on breast milk, which is a relatively secluded biologic compart-
ment with differences in drug concentrations and may possibly
have had drug resistance HIV variants that could be passed to the
infants; however, genotypic results from the majority of the infants
at the first time of diagnosis revealed the absence of resistant
strains. We previously showed that drug concentrations in breast
milk and bloodstream differ, and that biologically significant, but
suboptimal, amounts of antiretrovirals for treatment of HIV
infection could be passed to the infant via breastfeeding [13].
Breast milk concentrations of NVP were ,70% of maternal
plasma levels and in the infants were below the accepted target
trough concentration for treatment of HIV. 3TC concentrations
were ,2.5-fold higher in the breast milk than maternal plasma,
but below optimal plasma concentrations in the infant. The high
proportion of infants developing 3TC resistance mutations in this
report is consistent with the sub therapeutic concentrations of
3TC. The relatively low frequency of 3TC resistance among HIV-
infected infants exposed to maternal NVP/ZDV/3TC suggests
that NVP may be preventing or delaying emergence of 3TC
resistance. In contrast, the fact that all HIV-infected infants
exposed to maternal NFV/ZDV/3TC developed a 3TC mutation
may be explained by possible low levels of NFV in breast milk and
consequently low quantities transmitted to the infant [25]. The
appearance of K65R in one-quarter of the infants with resistance
(Table 3) is of concern, and this might be due to a high level of
3TC in the breast milk [13,19]. A follow-up genotypic analysis on
the detection of K65R mutation in breast milk is necessary. ZDV
concentrations were very low in breast milk, and, in the infants,
were below the limit of quantification most of the time. None of
the infants had mutations associated with ZDV resistance, which
Figure 2. Median viral load for infants (n = 12) who were PCR positive at birth in the KiBS, Kisumu, Kenya, 2003–2008. The trend of
median viral load at delivery was 2.8 log copies per ml, decreased ,3-fold at 2 wk, increased ,80-fold from 2 wk to 6 wk, and remained between 5
and 6 log copies per ml through 6 mo.
doi:10.1371/journal.pmed.1000430.g002
Table 1. HIV-1 drug resistance emergence among breastfeeding infants in the Kisumu Breastfeeding (KiBS) trial, Kenya, 2003–
2008.
Visit First HIV-PCR Positive Samples with Resistance (n)/Samples Tested (n)
0–2 wk 6 wk 14 wk 6 mo .6 mo
Delivery 12 0/7 5/12 10/12 11/12 —
2 wk 2 0/1 0/2 1/2 1/2 —
6 wk 6 — 1/6 1/6 1/6 —
14 wk 2 — — 2/2 2/2 —
6 mo 2 — — — 1/2 —
9–18 mo 8 — — — — 0/8
Total 32 0/8 6/20 14/22 16/24 0/8
Age refers to scheduled visit age at which samples were obtained.
doi:10.1371/journal.pmed.1000430.t001
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appears consistent with the low infant plasma ZDV concentrations
detected [13].
All infants in the KiBS trial received single-dose NVP prophy-
laxis at birth; however, no infants exposed to maternal NFV/
ZDV/3TC developed NVP drug resistance mutations. This
finding suggests that this maternal regimen provided an effective
‘‘tail’’ with 3TC via breast milk to reduce emergence of NVP drug
resistance mutations in the infants during the first few weeks when
infant NVP drug levels following single-dose NVP were still
present. In contrast, six of 15 infants exposed to both single-dose
NVP as well as maternal NVP through breast milk developed at
least one NNRTI mutation after 2 wk of age. This finding
corroborates other reports that showed that extended infant NVP
prophylaxis for PMTCT significantly reduces transmission of HIV
to infants [21,26], but with a high risk of developing resistance to
NVP [27,28]. Notably, no infants exposed to maternal NFV
developed drug resistance mutations which is consistent with
unpublished findings in a subset of women from the KIBS study
that NFV and its active metabolite (M8) transfer into breast milk in
low concentrations and the resulting concentrations in dried blood
spots of their breast-feeding infants for NFV were less than the
limit of quantification (LOQ)230ng/ml, and for M8 ,LOQ
232ng/ml [Weidle PJ, personal communication]. In another
study, NFV was present in extremely low concentrations in breast
milk and M8 was not detected [29]. Others have found no
detectable NFV in the plasma of breastfeeding infants whose
mothers were taking NFV as part of triple-combination antiret-
roviral therapy [25]. The subtype distribution observed in this
study follow a typical pattern of viruses circulating in this region
[30]. Furthermore, we did not observe preferential selection of
resistance in these infants based on subtypes.
The WHO recommends exclusive breastfeeding for HIV-
exposed infants in resource-limited settings where acceptable,
feasible, affordable, sustainable, and where safe replacement
feedings cannot be achieved [31]. Owing to this recommendation,
there is an urgent need to assess risks and benefits of antiretroviral
drugs that are less likely to be transmitted through breast milk,
thus reducing risk of exposure of infants to subtherapeutic levels of
antiretroviral drugs and hence reducing the risk of development of
HIV drug resistance among infants who become HIV infected
[13]. The differential development of drug resistance mutations in
the infant depending on the maternal antiretroviral regimen may
have implications for subsequent treatment options. This tradeoff
for low maternal-to-child transmission rates with the use of triple-
combination maternal antiretroviral therapy, which includes NVP
during breastfeeding, may require more complicated treatment
regimens (e.g., including a PI) to treat the small number of infants
who do become HIV infected in order to reduce development of
drug resistance. However, the options for antiretroviral regimens
available in most resource-limited settings are quite limited and so
may forestall introduction of ideal combinations that address our
findings. Because HIV drug resistance mutations in most infants
emerge over time, improvements in early infant HIV diagnosis
and treatment programs could mitigate the problem [24] before
Table 2. HIV drug resistance mutations among breastfeeding









HIV-PCR positive by 6 mo 15 9
Total with HIV drug
resistance mutations
7 9
NRTI resistance 5 9
NNRTI resistance 6 0
PI resistance 0 0
One mother was originally taking NVP/ZDV/3TC, but was changed to NFV/ZDV/
3TC at week 14.
doi:10.1371/journal.pmed.1000430.t002











1-0079-3 NVP/ZDV/3TC 0–1 wk 6 wk Y181C + G190A A/D
1-0195-6 NVP/ZDV/3TC 0–1 wk 6 mo K103KN A
1-0212-2 NVP/ZDV/3TC 6 mo 6 mo Y181C A
1-0230-2 NVP/ZDV/3TC 0–1 wk 14 wk M184V D/C
1-0472-8 NVP/ZDV/3TC 0–1 wk 14 wk K65R, M184V, K103N, Y181C A
1-0066-8 NVP/ZDV/3TC 0–1 wk 14 wk K65R + D67G + G190A A
1-0317-8 NVP/ZDV/3TC 14 wk 14 wk M184I +Y181C D
1-0289-1 NFV/ZDV/3TC 2 wk 14 wk M184V A
1-0410-4 NFV/ZDV/3TC 6 wk 6 wk M184I/V A/D
1-0357-5 NFV/ZDV/3TC 0–1 wk 14 wk M184V A
1-0457-9 NFV/ZDV/3TC 0–1 wk 6 wk K65R + M184V A
1-360-0 NFV/ZDV/3TC 0–1 wk 6 wk M184V A
1-0437-5 NFV/ZDV/3TC 14 wk 14 wk M184I A
1-0496-6 NFV/ZDV/3TC 0–1 wk 6 wk K65R + M184V A
1-0517-4 NFV/ZDV/3TC 0–1 wk 14 wk M184V A
1-0278-8 NFV/ZDV/3TC 0–1 wk 14 wk M184V A/D
doi:10.1371/journal.pmed.1000430.t003
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drug resistance mutations develop from exposure to maternal
antiretrovirals through breastfeeding.
In conclusion, the low mother-to-child HIV transmission rates
observed in the KiBS trial support the role of triple-combination
maternal antiretroviral therapy as a successful PMTCT interven-
tion among breastfeeding HIV-infected mothers [14]. However,
the data from this secondary analysis suggest that ingestion of
antiretroviral drugs through breast milk may have contributed to
the emergence of HIV drug resistance mutations in the infants, as
we observed an increasing frequency of infants with HIV drug
resistance mutations over the first 6 mo of life when maternal
antiretroviral therapy was given during breastfeeding. Infant drug
resistance mutation patterns, depending on the maternal regimen,
may have implications for subsequent HIV treatment of the small
number of infants, exposed to these maternal regimens, who
become HIV infected. Maternal antiretroviral regimens used for
PMTCT among HIV-infected breastfeeding women should be
evaluated to determine evolution of HIV drug resistance
mutations among infants who become HIV infected while exposed
to these regimens. PMTCT programs providing maternal antire-
troviral therapy during breastfeeding and those caring for infants
exposed to antiretroviral through breast milk will need to be
cognizant of this issue and consider monitoring these infants more
closely and tailoring their treatment accordingly.
Supporting Information
Text S1 Protocol.
Found at: doi:10.1371/journal.pmed.1000430.s001 (1.24 MB
PDF)
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Editors’ Summary
Background. Globally, more than 2 million children are
infected with the human immunodeficiency virus (HIV) that
causes acquired immunodeficiency syndrome (AIDS), and
half a million children are newly infected every year. These
infections are mainly the result of mother-to-child
transmission (MTCT) of HIV during pregnancy, labor and
delivery, or through breastfeeding. MTCT can be greatly
reduced by treating HIV-positive mothers and their babies
with antiretroviral drugs (ARVs). Without ARVs, up to half of
babies born to HIV-positive mothers become infected with
HIV. This rate of transmission falls to below 5% if a
combination of three ARVs is given to the mother
throughout pregnancy. Unfortunately, this triple-ARV
therapy is too expensive for use in the resource-limited
countries where most MTCT occurs. Instead, many such
countries have introduced simpler, shorter ARV regimens
such as a daily dose of zidovudine (a nucleoside reverse
transcriptase inhibitor or NRTI) given to HIV-positive women
during late pregnancy coupled with single-dose nevirapine
(a non-nucleoside reverse transcriptase inhibitor or NNRTI) at
the onset of labor, zidovudine and lamivudine (another NRTI)
during labor and delivery, and single-dose nevirapine given
to the baby at birth.
Why Was This Study Done? More than 95% of HIV-
exposed children are born in resource-limited settings where
breastfeeding is the norm and is crucial for child survival
even though it poses a risk of HIV transmission. Conse-
quently, several recent studies have investigated whether
MTCT can be further reduced by giving the mother ARVs
while she is breastfeeding. In the Kisumu Breastfeeding
Study (KiBS), for example, researchers assessed the effects of
giving zidovudine, lamivudine, and either nevirapine or
nelfinavir (a protease inhibitor) to HIV-infected women from
34 weeks of pregnancy through 6 months of breastfeeding.
The results of KiBS indicate that this approach might be a
safe, feasible way to reduce MTCT (see the accompanying
paper by Thomas and colleagues). However, low amounts of
nevirapine and lamivudine are transferred from mother to
infant in breast milk and this exposure to ARVs could induce
the development of resistance to ARVs among HIV-infected
infants. In this KiBS substudy, the researchers investigate
whether HIV drug resistance emerged in any of the HIV-
positive infants in the parent study.
What Did the Researchers Do and Find? In KiBS, 32
infants were HIV-positive at 24 months old; 24 were HIV-
positive at 6 months old when their mothers stopped taking
ARVs and when breastfeeding was supposed to stop. The
researchers analyzed blood samples taken from these infants
at various ages and from their mothers for the presence of
HIV drug resistance mutations (DNA changes that make HIV
resistant to killing by ARVs). They detected no resistance
mutations in samples taken from 2-week old HIV-positive
infants or from the infants who became infected after the
age of 6 months. However, they found resistance mutations
in a third and two-thirds of samples taken from 6-week and
6-month old HIV-positive infants, respectively. The common-
est mutations conferred resistance to lamivudine and
nevirapine. Moreover, resistance mutations were present in
samples taken from all the HIV-positive infants whose
mothers who had received nelfinavir but in only half those
taken from infants whose mothers who had received
nevirapine. Finally, most of the mothers of HIV-positive
infants had no HIV drug resistance mutations, and only one
mother-infant pair had an overlapping pattern of HIV drug
resistance mutations.
What Do These Findings Mean? These findings indicate
that, in this KiBS substudy, the emergence of HIV drug
resistance mutations in HIV-infected infants whose mothers
were receiving ARVs occurred between 2 weeks and 6
months after birth. The pattern of mutations suggests that
drug resistance most likely arose through exposure of the
infants to low levels of ARVs in breast milk rather than
through MTCT of drug-resistant virus. These findings need
confirming but suggest that infants exposed to ARVs
through breast milk—a situation that may become
increasingly common given the reduction in MTCT seen in
KiBS and other similar trials—should be carefully monitored
for HIV infection. Providers should consider the mothers’
regimen when choosing treatment for infants who are found
to be HIV-infected despite maternal triple drug prophylaxis.
Infants exposed to a maternal regimen with NNRTI drugs
should receive first-line therapy with lopinavir/ritonavir, a
protease inhibitor. The significance of the NRTI mutations
such as M184V with regard to response to therapy needs
further evaluation. The M184V mutation may result in
hypersensitization to other NRTI drugs and delay or reverse
zidovudine resistance. Given the limited availability of
alternative drugs for infants in resource-limited settings,
provision of the standard WHO-recommended first-line NRTI
backbone, which includes 3TC, with enhanced monitoring of
the infant to ensure virologic suppression, could be
considered. Such an approach should reduce both illness
and morbidity among infants who become HIV positive
through breastfeeding.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/
10.1371/journal.pmed.1000430.
N The accompanying PLoS Medicine Research article by
Thomas and colleagues describes the primary findings of
the Kisumu Breastfeeding Study
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N HIV InSite has comprehensive information on HIV/AIDS
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including informa-
tion on children, HIV, and AIDS and on preventing mother-
to-child transmission of HIV (in English and Spanish)
N UNICEF also has information about children and HIV and
AIDS (in several languages)
N The World Health organization has information on mother-
to-child transmission of HIV (in several languages), and
guidance on the use of ARVs for preventing MTCT
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